Zovighian Bernard J 4
4 · Edwards Lifesciences Corp · Filed Dec 10, 2025
Insider Transaction Report
Form 4
Zovighian Bernard J
DirectorCEO
Transactions
- Exercise/Conversion
Common Stock
2025-12-08$59.26/sh+25,350$1,502,157→ 106,326 total - Sale
Common Stock
2025-12-08$85.21/sh−21,487$1,831,006→ 84,839 total - Gift
Common Stock
2025-12-09−3,863→ 80,976 total - Sale
Common Stock
2025-12-10$83.45/sh−3,863$322,367→ 8,596.551 total(indirect: By Trust) - Exercise/Conversion
Employee Stock Option (Right to Acquire)
2025-12-08−25,350→ 25,350 totalExercise: $59.26Exp: 2026-05-07→ Common Stock (25,350 underlying)
Holdings
- 3,605.849(indirect: By 401(k))
Common Stock
Footnotes (3)
- [F1]The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 28, 2025.
- [F2]This transaction was executed in multiple trades at prices ranging from $84.63 to $85.57. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
- [F3]These options were granted on May 8, 2019 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments.